Annual Meeting Schedule

Browse the 32nd Annual Meeting schedule by day:

Friday, Nov. 10

Update Session

8 8:05 a.m. Presidential Welcome
Lisa H. Butterfield, PhD – UPMC Hillman Cancer Center
8:05 8:35 a.m. Update Session

Keynote Address

8:35 8:40 a.m. Introduction
Lisa H. Butterfield, PhD – UPMC Hillman Cancer Center
8:40 9:20 a.m. The CAR T Revolution in Leukemia
Stephan Grupp, MD, PhD – University of Pennsylvania
9:20 9:25 a.m. Q&A and Closing Remarks
Stephan Grupp, MD, PhD – University of Pennsylvania

Science Behind the Therapy: Mechanisms of Efficacy & Toxicity

Co-Chairs:

Kevan Herold, MD – Yale University
Arlene Sharpe, MD, PhD – Harvard Medical School

9:25 9:35 a.m. Introduction
Arlene Sharpe, MD, PhD - Harvard Medical School
9:35  9:55 a.m. Clinical Overview of Checkpoint Inhibitors
Jeffrey A. Sosman, MD Feinberg School of Medicine
9:55 10:15 a.m. Autoimmune Endocrinopathies
Kevan Herold, MD – Yale University
10:15  10:30 a.m. Break
10:30 10:50 a.m.

Colitis
Michael Dougan, MD, PhD – Massachusetts General Hospital

10:50  11:10 a.m. Cardiovascular Autoimmunity
Andrew Lichtman, MD, PhD - Brigham and Women's Hospital
11:10  11:30 a.m. Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analyses of Patient, Protocol and Product Attributes
Mark J. Gilbert, MD - Juno Therapeutics, Inc.
11:30 11:45 a.m. Oral Abstract Presentation
11:45 a.m.  Noon Oral Abstract Presentation

Late-Breaking Abstract Session I

Noon  12:15 p.m. Oral Abstract Presentation
12:15 12:30 p.m. Oral Abstract Presentation
12:30 2 p.m. Lunch & Poster Viewing Session

Clinical Trials: New Agents

Co-Chairs:
1:45 2 p.m. Oral Abstract Presentation
2 2:15 p.m. Oral Abstract Presentation
2:15 2:30 p.m. Oral Abstract Presentation
2:30  2:45 p.m. Oral Abstract Presentation
2:45 3 p.m. Oral Abstract Presentation
3 3:15 p.m. Oral Abstract Presentation
3:15 3:30 p.m. Oral Abstract Presentation

Building Personalized Vaccines and Technologies for Hematologic Malignancies and Solid Tumors

Co-Chairs:

Catherine J. Wu, MD – Dana-Farber Cancer Institute
Matthew M. Gubin, PhD – Washington University of Medicine

2 2:05 p.m. Introduction
Matthew M. Gubin, PhD – Washington University School of Medicine
2:05 2:25 p.m. Preclinical & Mouse Models
Matthew M. Gubin, PhD – Washington University School of Medicine
2:25 2:45 p.m. Tumor Vaccines in AML
David E. Avigan, MD – Beth Israel Deaconess Medical Center
2:45 3:05 p.m. Improvement in Epitope Discovery
Catherine J. Wu, MD – Dana-Farber Cancer Institute
3:05 3:20 p.m. Oral Abstract Presentation

High Impact Clinical Trial Results

Chair:

Mario Sznol, MD - Yale School of Medicine

3:30 3:35 p.m. Introduction
Mario Sznol, MD – Yale School of Medicine
3:35 – 3:50 p.m. Oral Abstract Presentation
3:50 4:05 p.m. Oral Abstract Presentation
4:05 4:20 p.m.
Oral Abstract Presentation
4:20 4:35 p.m. Oral Abstract Presentation
4:35 4:50 p.m. Expert Discussant
Samir Khleif, MD – Georgia Cancer Center
4:50 5:05 p.m. Break

Concurrent Session I: Oncolytic Viruses and Intratumoral Therapies

Co-Chairs:

Howard L. Kaufman, MD, FACS - Replimune Group, Inc.
Samuel Rabkin, PhD - Massachusetts General Hospital 

5:05 5:10 p.m. Introduction
Howard L. Kaufman, MD, FACS – Replimune Group, Inc.
5:10 5:30 p.m. CAVATAK and Pembrolizumab Results
Howard L. Kaufman, MD, FACS – Replimune Group, Inc.
5:30 5:50 p.m. Oncolytic Herpes Simplex Virus in Glioblastoma
Samuel Rabkin, PhD – Massachusetts General Hospital 
5:50 6:10 p.m. Oncolytic Virus Clinical Data
Brian D. Lichty, PhD – McMaster University
6:10 6:25 p.m. Oral Abstract Presentation
6:25 – 6:30 p.m. Closing Remarks
Samuel Rabkin, PhD – Massachusetts General Hospital

Concurrent Session II: Energizing Immune Cell Metabolism in Cancer

Co-Chairs:

Nicholas P. Restifo, MD - National Cancer Institute
Susan M. Kaech, PhD - Yale University

5:05 – 5:25 p.m. Anti-Tumor T Cells: You Are What You Eat
Susan M. Kaech, PhD – Yale University
5:25 – 5:45 p.m. Metabolic Control of T Cell Epigenetics
Nicholas P. Restifo, MD – National Cancer Institute
5:45 – 6:05 p.m. Metabolic Changes in Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh
6:05 – 6:20 p.m. Oral Abstract Presentation
6:20 – 6:35 p.m. Oral Abstract Presentation
6:30 – 7:45 p.m. Poster Reception
8 – 9 p.m. Presidential Reception & Membership Business Meeting

Saturday, Nov. 11

8:05 a.m. Organizer Welcome
Charles G. Drake, MD, PhD – Columbia University Medical Center
8:05 – 8:20 a.m. Presentation
8:20 8:35 a.m. Presentation

Smalley Keynote

8:35 8:40 a.m. Introduction
Lisa H. Butterfield, PhD – UPMC Hillman Cancer Center
8:40 9:20 a.m. Activation of Innate and Adaptive Immunity as an In Situ Cancer Vaccine
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
9:20 9:25 a.m. Q&A and Closing Remarks
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison

Mechanisms of Acquired Resistance to Immunotherapies

Co-Chairs:

Katerina Politi, PhD - Yale School of Medicine
Antoni Ribas, MD, PhD - University of California, Los Angeles

9:25 9:30 a.m. Introduction
Katerina Politi, PhD – Yale School of Medicine
9:30 9:55 a.m. Acquired Resistance Checkpoint Inhibitors in Lung Cancer
Katerina Politi, PhD – Yale School of Medicine
9:55 10:20 a.m. Acquired Resistance
Antoni Ribas, MD, PhD – University of California, Los Angeles
10:20 10:45 a.m. Break
10:45 11:10 a.m. Acquired Resistance in Melanoma
Annette Paschen, MD – University Hospital Essen
11:10 11:25 a.m. Oral Abstract Presentation
11:25 11:40 a.m. Oral Abstract Presentation
11:40 11:55 a.m. Oral Abstract Presentation
11:55 a.m.  Noon Closing Remarks
Antoni Ribas, MD, PhD – University of California, Los Angeles

Late Breaking Abstract Session II

12 12:15 p.m. Oral Abstract Presentation
12:15 12:30 p.m. Oral Abstract Presentation
12:30 2 p.m. Lunch

Presidential Session

2 – 2:05 p.m.  Introduction
Lisa H. Butterfield, PhD – UPMC Hillman Cancer Center
2:05 – 2:20 p.m.  Oral Abstract Presentation
2:20 – 2:35 p.m. Oral Abstract Presentation
2:35 – 2:45 p.m. Expert Discussant
2:45 – 3 p.m. Oral Abstract Presentation
3 – 3:15 p.m. Oral Abstract Presentation
3:15 – 3:25 p.m. Expert Discussant  

Tumor Immunology 101 (Physician/Nurse/Pharmacy Track)

Co-Chairs:

Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Eleni Yeatras, RPh, BCOP – Johns Hopkins Kimmel Center at Sibley Memorial Hospital

2:05 p.m. Introduction
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
2:05 2:30 p.m. Immunology 101 for the Non-Immunologist
Yvonne Saenger, MD – Columbia University Medical Center
2:30 2:55 p.m. Basic Principles of Tumor Immunotherapy
Michael K. Wong, MD, PhD, FRCPC – MD Anderson Cancer Center
2:55 3:20 p.m. Drug Classification & MOAs
Lisa M. Cordes, PharmD, BCACP, BCOP – National Cancer Institute
3:20 3:25 p.m. Closing Remarks
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
3:25 3:40 p.m. Break

Economics of Immunotherapies and Immunotherapy Combinations

Co-Chairs:

Michael B. Atkins, MD – Georgetown Lombardi Comprehensive Cancer Center
Bruce Levine, PhD – Abramson Cancer Center

3:25 3:27 p.m. Introduction
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
3:27 3:42 p.m. Report on Economics of Checkpoint Inhibitors in Melanoma
Ahmad Tarhini, MD, PhD – University of Pittsburgh Cancer Institute
3:42 3:57 p.m. Report on Economics of Adoptive Cell Therapy
Richard Maziarz, MD – Oregon Health & Science University
3:57 4 p.m. Q&A and Closing Remarks
4:15 p.m. Plenary Session Break

Clinical Trials: Novel Combinations

Co-Chairs:
3:30 – 3:45 p.m. Oral Abstract Presentation
3:45 – 4 p.m. Oral Abstract Presentation
4 – 4:15 p.m. Oral Abstract Presentation
4:15 4:30 p.m. Oral Abstract Presentation
4:30 - 4:45 p.m. Oral Abstract Presentation
4:45 – 5 p.m. Oral Abstract Presentation
5 – 5:15 p.m. Oral Abstract Presentation
5:15 – 5:30 p.m. Oral Abstract Presentation
5:30 – 5:45 p.m. Oral Abstract Presentation
5:45 – 6 p.m. Oral Abstract Presentation

Clinical Management (Physician/Nurse/Pharmacy Track)

Co-Chairs: 

Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Eleni Yeatras, RPh, BCOP – Johns Hopkins Kimmel Center at Sibley Memorial Hospital

3:40 3:45 p.m. Introduction
Eleni Yeatras, RPh, BCOP – Johns Hopkins Kimmel Center at Sibley Memorial Hospital
3:45 4:15 p.m. General Concepts of Toxicity Management
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
4:15 4:35 p.m. Pharmacological Management of irAEs
Nathan Dahl, PharmD, R.Ph – Mayo Clinic
4:35 5 p.m. Panel Discussion: Management of Complex Adverse Events
Moderator: Eleni Yeatras, RPh, BCOP – Johns Hopkins Kimmel Center at Sibley Memorial Hospital
Panel: Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Nathan Dahl, PharmD – Mayo Clinic
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
5 5:15 p.m. Oral Abstract Presentation
5:15 5:30 p.m. Audience Question & Answer
Moderator: Eleni Yeatras, RPh, BCOP – Johns Hopkins Kimmel Center at Sibley Memorial Hospital 

Emerging Models & Imaging

Co-Chairs:

Daniel Thorek, PhD – Johns Hopkins University School of Medicine
Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health

4:15 4:20 p.m. Introduction
4:20 4:40 p.m. Imaging Immunity - Developing a Spatiotemporal Understanding of Host Defense and Tumor Immunity
Ronald Germain, MD, PhD – National Institute of Allergy and Infectious Diseases, National Institute of Health
4:40 5 p.m. TBD
Daniel Thorek, PhD – Johns Hopkins University School of Medicine
5:20 p.m. Oral Abstract Presentation
5:20 5:35 p.m. Oral Abstract Presentation
5:35 5:40 p.m. Closing Remarks

Award Ceremony

6:00 – 6:30 p.m. Award Ceremony
Lisa H. Butterfield, PhD – UPMC Hillman Cancer Center
6:30 8 p.m. Evening Poster Reception & Viewing
8:30 11:30 p.m. The CheckPoints Party

Sunday, Nov. 12

8:05 a.m. Organizer Welcome
Marcela V. Maus, MD, PhD Massachusetts General Hospital 

Genetically Modified Cell Therapy

Co-Chairs:

Marcela V. Maus, MD, PhD – Massachusetts General Hospital 
Helen E. Heslop, MD – Baylor College of Medicine

Carl H. June, MD – University of Pennsylvania

8:05 8:30 a.m. Gene Edited CAR T Cells
Martin Pule, PhD – University College London
8:30 8:55 a.m. Updates in CAR T cells
Crystal L. Mackall, MD – Stanford University
8:55 9:20 a.m. Genetically Modified T Cells for Solid Tumors
Stephen Gottschalk, MD – Baylor College of Medicine
9:20 9:45 a.m. Late-Breaking: CD19 CAR Enter the Mainstream
Glenn Dranoff, MD – Novartis Institute of Biomedical Research
9:45 10 a.m. Oral Abstract Presentation
10 – 10:15 a.m. Oral Abstract Presentation

Hot Topic Symposium: Advancing the Field: Can Physics and Mathematics Impact the Development of Tumor Immunotherapy?

Co-Chairs
Howard Kaufman, MD, FACSReplimune Group, Inc.
Herbert Levine, PhDRice University

10:30 – 10:35 a.m. Welcome and Introductions
10:35 – 10:55 a.m. Overview of the Immunotherapy Field
Francesco M. Marincola, MD – AbbVie Inc.
10:55 – 11:15 a.m. Emerging Topics
Thomas F. Gajewski, MD, PhD – University of Chicago
11:15 – 11:35 a.m. Challenges in Clinical Development
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
11:35 – 11:55 a.m. T Cell Repertoire
Curtis Callan, PhD – Princeton University
11:55 – 12:15 p.m. Systems of Biology Modeling of the Immune System
Doron Levy, PhD – University of Maryland
12:15 – 12:35 p.m. Modeling the Fitness Costs of Neoantigens
Benjamin Greenbaum, PhD – Tisch Cancer Institute
12:35 – 1 p.m. Panel Discussion